Dexorgen, Inc. is an advanced biotechnology company based in Gaithersburg, MD, specializing in providing simple and high throughput solutions for drug discovery. With their patented ACTOne technology, they offer live cell based assays for efficient screenings of new compounds in a physiologically accurate environment, making them a leader in the production of commercially available cell lines that target phosphodiesterases (PDEs). Dexorgen also offers unique biochemical assay kits and specialty dyes, aiming to deliver high-quality products that aid scientists in the discovery process.
With a strong focus on compound screening and target selectivity profiling, Dexorgen provides a range of services including assay development, mechanism of action characterization, reagent development, primary cell culture, and cell engineering. They have actively participated in federal collaborations such as Tox21, developing assays for nuclear hormone receptors and mitochondria toxicity, and are currently working on evaluating toxicities on TSHR and TRHR. Dexorgen collaborates with pharmaceutical companies, biotech companies, universities, and governmental institutes, offering their expertise and innovative solutions to advance scientific research.
Generated from the website